This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tryptophan 2,3-dioxygenase (TDO2; TDO)	<i>In vitro</i> studies suggest a class of TDO inhibitors could help treat cancer. Synthesis and <i>in vitro</i> testing of pyridylethenylindole analogs identified a lead compound as a selective, low micromolar inhibitor of TDO. A forthcoming publication in an undisclosed journal will show that in mouse models of TDO-expressing mastocytoma, pretreatment with the lead compound prevented tumor growth compared with no treatment. SciBX 4(29); doi:10.1038/scibx.2011.823 Published online July 28, 2011	Patented by the Ludwig Institute for Cancer Research and the University of Namur; available for licensing	Dolušić, E. <i>et al. J. Med. Chem.</i> ; published online July 4, 2011; doi:10.1021/jm2006782 Contact: Raphaël Frédérick, University of Namur, Namur, Belgium e-mail: raphael.frederick@fundp.ac.be